WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue for the first quarter of 2007. The Company expects to record total revenues of approximately $23 million in the first quarter of 2007, compared to $11.0 million in total revenues in the first quarter of 2006, prior to the acquisition of ANTARA® (fenofibrate) capsules.
